384 reports of this reaction
2.8% of all METHIMAZOLE reports
#4 most reported adverse reaction
HYPERTHYROIDISM is the #4 most commonly reported adverse reaction for METHIMAZOLE, manufactured by AiPing Pharmaceutical, Inc.. There are 384 FDA adverse event reports linking METHIMAZOLE to HYPERTHYROIDISM. This represents approximately 2.8% of all 13,542 adverse event reports for this drug.
Patients taking METHIMAZOLE who experience hyperthyroidism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERTHYROIDISM is a less commonly reported adverse event for METHIMAZOLE, but still significant enough to appear in the safety profile.
In addition to hyperthyroidism, the following adverse reactions have been reported for METHIMAZOLE:
The following drugs have also been linked to hyperthyroidism in FDA adverse event reports:
HYPERTHYROIDISM has been reported as an adverse event in 384 FDA reports for METHIMAZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERTHYROIDISM accounts for approximately 2.8% of all adverse event reports for METHIMAZOLE, making it a notable side effect.
If you experience hyperthyroidism while taking METHIMAZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.